18 April 2018 | News
This move expands the portfolio of cancer care medicines Mundipharma will provide in Mexico.
Image credit- legalraasta.com
Mundipharma is partnering with Caris Life Sciences, a leading US biotechnology company, to provide the exclusive sales, promotion, marketing and distribution of its tumor profiling service, Caris Molecular Intelligence, in Mexico.
Caris Molecular Intelligence is a patented and proprietary service that uses a combination of technologies, including Next-Generation Sequencing (NGS), to examine each tumour at the various biological stages of cancer, which provides individualised data about a patient’s cancer. This information enables oncologists to make informed treatment decisions based on the unique molecular characteristics of each patient’s cancer.
Providing nuanced understanding of tumour profiling studies helps identify patients who will benefit most from targeted therapies.
This move expands the portfolio of cancer care medicines Mundipharma will provide in Mexico. More importantly, the service has the potential to make a real difference to patients’ lives by empowering healthcare professionals to more quickly identify treatment options, from all that are available, especially for rare and aggressive cancers.
Mundipharma already has a successful partnership in place with Caris Life Sciences to provide this service in Malaysia and the two organisations are exploring other countries in which they could work together to benefit cancer patients.
Mundipharma CEO, Raman Singh, said “As well as making new medicines available via our own research and development pipeline, Mundipharma is constantly exploring strategic partnerships that will bring patients access to important treatments.
“While cancer treatments have significantly advanced over the years, current cancer care options are still failing too many patients. With the introduction of Caris Molecular Intelligence, we’re proud that oncologists will now able to recommend better personalized treatments to specifically target patients’ cancer. We believe this is a game-changer for oncology in Mexico.”